Clinical and hematological improvement in a patient receiving danazol therapy for myelofibrosis with myeloid metaplasia.
We report the positive effect of danazol on clinical and hematological data in a patient with myelofibrosis and myeloid metaplasia. Severe cytopenia was corrected within 2 months and was maintained for an additional 2-month period. Myeloid metaplasia (lymph nodes and skin lesions) was greatly reduced. The patient experienced no side effects. We propose further trials to confirm the utility of this agent in this disease.
Chabannon
C
C
Service d'Hématologie Clinique, Hôpital Albert-Michallon, Grenoble, France.
Pegourie
B
B
Sotto
J J
JJ
Hollard
D
D
D003613:Danazol / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011245:Pregnadienes / Q000627:therapeutic use*; D055728:Primary Myelofibrosis / Q000150:complications / Q000188:drug therapy*
D011245:Pregnadienes; D003613:Danazol